Money Control Place
  • Politics
  • Business
  • Stocks
  • Investing
  • Politics
  • Business
  • Stocks
  • Investing

Money Control Place

Investing

5 Small Biotech ETFs (Updated 2023)

by June 14, 2023
June 14, 2023
5 Small Biotech ETFs (Updated 2023)

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants to gain leverage in multiple biotech companies via one investment vehicle.

The life science sector can certainly be risky, and ETFs are a good way to enter more safely than by investing in standalone stocks. A key advantage is that even if one company in the ETF takes a hit, the impact will be less direct.

1. Principal Healthcare Innovators ETF (NASDAQ:BTEC)

Company Profile

AUM: US$54.27 million

The Principal Healthcare Innovators ETF tracks US-listed healthcare stocks with a focus on those researching and developing innovative medicines and therapies. This fund was first introduced to the market in August 2016 and invests at least 80 percent of its assets in mid- and small-cap companies.

There are 233 holdings in this biotechnology fund. Its top holdings are Exact Sciences (NASDAQ:EXAS) with a weight of 3.2 percent; Seagen (NASDAQ:SGEN), weighing in at 2.85 percent; and Alnylam Pharmaceuticals (NASDAQ:ALNY) at a 2.69 percent weightage.

2. Virtus LifeSci Biotech Products ETF (ARCA:BBP)

Company Profile

AUM: US$18.27 million

Launched in December 2014, the Virtus LifeSci Biotech Products ETF tracks biotech companies that have completed multiple human clinical trials and have received US Food and Drug Administration approval to sell and market a drug.

There are 57 holdings in this biotechnology fund, with about 60 percent being mid- to large-cap stocks. Its top holdings include ImmunoGen (NASDAQ:IMGN), weighing 4.84 percent; Aurinia Pharmaceuticals (NASDAQ:AUPH) at a weight of 3.45 percent; and Apellis Pharmaceuticals (NASDAQ:APLS), weighing 2.93 percent.

3. Loncar Cancer Immunotherapy ETF (NSD:CNCR)

Company Profile

AUM: US$13.46 million

The Loncar Cancer Immunotherapy ETF was launched in October 2015, and tracks 32 holdings focused on cancer therapies that use the body’s own immune system. Of its holdings, the majority are small caps in the clinical-stage biotech sector, with a handful of large-cap immunotherapy leaders.

The top biotech stocks in this ETF are Merus (NASDAQ:MRUS) at 6.1 percent; Arcelix (NASDAQ:ACLX) at a 5.15 percent weight; and Iovance Biotherapeutics (NASDAQ:IOVA) with a 4.94 percent weightage.

4. Virtus LifeSci Biotech Clinical Trials ETF (ARCA:BBC)

Company Profile

AUM: US$12.29 million

The Virtus LifeSci Biotech Clinical Trials ETF tracks the performance of select biotechnology companies in the clinical trial stage. This fund invests nearly 54 percent of its assets in small-cap companies.

There are 123 holdings included in this biotechnology fund, which was launched in December 2014. Its top holdings are Madrigal Pharmaceuticals (NASDAQ:MDGL), weighing 3.79 percent; TG Therapeutics (NASDAQ:TGTX), weighing 2.46 percent; and Protagonist Therapeutics (NASDAQ:PTGX), weighing 2.3 percent.

5. Franklin Genomic Advancements ETF (CBOEBZX:HELX)

Company Profile

Launched in February 2020, the Franklin Genomic Advancements ETF is the newest small biotech ETF on this list. According to ETFdb.com, this fund ‘invests in companies that stand to benefit from advancements in genomic-based research techniques and technologies.’

There are 58 holdings in this biotechnology ETF, with over 91 percent being mid- to large-cap stocks. Its top holdings include Thermo Fisher Scientific (NYSE:TMO), weighing 6.09 percent; Repligen (NASDAQ:REGN) at a weight of 5.6 percent; and Danaher (NYSE:DHR), weighing 5.41 percent.

Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com
0
FacebookTwitterGoogle +Pinterest
previous post
How to Invest in Vanadium (Updated 2023)
next post
Nevada approves funding to replace crumbling tribal school following widespread community outcry

Related Posts

Miners Facing Financing Frustration, Where Will the Money...

March 19, 2024

Yvonne Blaszczyk: Gold to Keep Rising as Global...

February 28, 2025

Copper Price Update: Q1 2024 in Review

April 20, 2024

Why Nevada Could be the Next Lithium Frontier

October 18, 2023

Fabi Lara: Uranium Thesis is Back, How to...

January 29, 2025

4 Factors That Drive Silver Demand (Updated 2023)

October 27, 2023

Could the Silver Price Really Hit US$100 per...

August 8, 2023

Horizon Minerals

June 24, 2024

Canada Nickel Receives Equity Investment from Samsung SDI

January 13, 2024

NextSource Materials Provides Update on Molo Graphite Mine...

February 6, 2024

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest

    • Run Your Stock Portfolio Like a Pro Sports Team

    • Leadership Rotation Could Confirm Corrective Phase

    • Breakouts, Momentum & Moving Averages: 10 Must-See Stock Charts Right Now

    • 1911 Gold Temporarily Suspends Operations at True North Complex due to Bissett Evacuation Order

    • Ontario Backs Down on Key Bill 5 Provisions, Echoes BC’s Mining Debate

    • Appeals Court Grants Trump Temporary Reprieve on Tariffs, “TACO” Taunts Gain Steam

    Categories

    • Business (1,223)
    • Investing (2,503)
    • Politics (3,699)
    • Stocks (1,614)
    • Uncategorized (20)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: MoneyControlPlace.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 moneycontrolplace.com | All Rights Reserved